CRISPR Therapeutics AG
CRSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4,235,070 | $2,924,495 | $3,363,873 |
| - Cash | $286,497 | $197,132 | $235,184 | $298,257 |
| + Debt | $192,768 | $215,452 | $219,358 | $223,693 |
| Enterprise Value | – | $4,253,390 | $2,908,669 | $3,289,309 |
| Revenue | $889 | $0 | $865 | $35,000 |
| % Growth | – | -100% | -97.5% | – |
| Gross Profit | -$63,804 | -$45,153 | -$56,644 | $35,000 |
| % Margin | -7,177.1% | – | -6,548.4% | 100% |
| EBITDA | -$101,389 | -$224,675 | -$143,688 | -$59,746 |
| % Margin | -11,404.8% | – | -16,611.3% | -170.7% |
| Net Income | -$106,441 | -$208,549 | -$135,996 | -$37,311 |
| % Margin | -11,973.1% | – | -15,722.1% | -106.6% |
| EPS Diluted | -1.17 | -2.4 | -1.58 | -0.44 |
| % Growth | 51.3% | -51.9% | -259.1% | – |
| Operating Cash Flow | -$84,634 | -$113,880 | -$53,947 | -$50,031 |
| Capital Expenditures | -$74 | -$117 | -$206 | -$254 |
| Free Cash Flow | -$84,708 | -$113,997 | -$54,153 | -$50,285 |